Volume 15, I – Spring 2006

In 2005, two members of Act-Up Paris went on a mission to Saint Petersburg and Moscow in Russia.

‘During the summer of 1992 an International AIDS Conference took place in Amsterdam and one night towards the end of the coverage on TV a miracle happened.

The following is part of the speech given by Mark Harrington at the Boehringer Ingelheim symposium on HIV titled ”Past and Future“.

The following article scans the life of the ECAB (European Community Advisory Broard) from when the idea was conceived to the current changes it makes within Europe today.

...in 2001, for the first time, representatives from the countries which are members of the UN organisation and have signed the Declaration of Human Rights, formally also declared that a disease was threatening the planet’s security: AIDS. Governments accepted that AIDS was a huge international problem...

The following article looks at the problem of treatment access to drug and/or alcohol users. More specifically focusing on the situation of IDUs who are co-infected with HIV and HCV.

HIV/AIDS is fast becoming a major threat to health, economic stability and human development in many parts of the European Region.[ref 1, 2]

Like protease and reverse transcriptase, integrase is an enzyme used by HIV to reproduce itself within the infected cell. Since the 1990s scientists have been looking for drugs that would work by inhibiting integrase.

It has been almost 10 years since the first cases of ”Crix belly“ were identified, very shortly after the introduction of protease inhibitors and the use of triple combination antiretroviral therapy (ART).

For the past two years, our European Institutions have renewed -on several occasions – their commitment to play a greater role responding to HIV/AIDS in Europe.

New generation of vaginal microbicides - New candidate microbicides will be based on proteins, molecules, antiretrovirals, chemokines and even bacteria

The 4th European HIV Drug Resistance Workshop brought together about 350 virologists, clinicians, epidemiologists and representatives from the ppharmaceutical and diagnostic industry.

It is the mandate of the EATG to be involved in consulting with companies and bodies conducting clinical research in people with HIV/AIDS.